Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

[Risk of thrombosis with oral contraceptives: value of a thrombophilia screening test].

Bauersachs R, Kuhl H, Lindhoff-Last E, Ehrly AM.

Vasa. 1996;25(3):209-20. Review. German.

PMID:
8967151
2.

[Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives].

Bauersachs R, Lindhoff-Last E, Ehrly AM, Kuhl H.

Zentralbl Gynakol. 1996;118(5):262-70. Review. German.

PMID:
8701622
3.

Oral contraception and thrombophilia.

Blickstein D, Blickstein I.

Curr Opin Obstet Gynecol. 2007 Aug;19(4):370-6. Review.

PMID:
17625421
4.

[Contraceptive agents and risk of thrombosis].

Maurer-Major E, Keller PJ.

Praxis (Bern 1994). 1997 Oct 1;86(40):1543-8. Review. German.

PMID:
9417570
6.

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.

Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Langhorne P, Brenkel I, Regan L, Greer I.

Health Technol Assess. 2006 Apr;10(11):1-110. Review.

7.

Haemostatic changes and the oral contraceptive pill.

Norris LA, Bonnar J.

Baillieres Clin Obstet Gynaecol. 1997 Sep;11(3):545-64. Review.

PMID:
9488791
8.

Screening for a prothrombotic diathesis in patients attending family planning clinics.

Kalev M, Day T, Van de Water N, Ockelford P.

N Z Med J. 1999 Sep 24;112(1096):358-61.

PMID:
10587055
9.

Thrombotic risk factors and oral contraception.

Bokarewa MI, Falk G, Sten-Linder M, Egberg N, Blombäck M, Bremme K.

J Lab Clin Med. 1995 Sep;126(3):294-8.

PMID:
7665978
10.

Contraceptive choices in women with coagulation disorders.

Comp PC, Zacur HA.

Am J Obstet Gynecol. 1993 Jun;168(6 Pt 2):1990-3. Review.

PMID:
8512043
11.

A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.

Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, Bouma BN, Büller HR, Rosing J.

Thromb Haemost. 2000 Jul;84(1):15-21.

PMID:
10928463
12.

Prothrombotic effects and clinical implications of third-generation oral contraceptives use.

Lippi G, Manzato F, Brocco G, Franchini M, Guidi G.

Blood Coagul Fibrinolysis. 2002 Jan;13(1):69-72.

PMID:
11994571
13.

Screening for activated protein C resistance before oral contraceptive treatment: a pilot study.

Palareti G, Legnani C, Frascaro M, Flamigni C, Gammi L, Gola G, Fuschini G, Coccheri S.

Contraception. 1999 May;59(5):293-9.

PMID:
10494482
14.

Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor.

van Vliet HA, Bertina RM, Dahm AE, Rosendaal FR, Rosing J, Sandset PM, Helmerhorst FM.

J Thromb Haemost. 2008 Feb;6(2):346-51.

15.

Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.

Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W.

Thromb Haemost. 1996 Nov;76(5):729-34.

PMID:
8950781
16.

Risk of venous thromboembolism with third-generation oral contraceptives: A review.

Weiss G.

Am J Obstet Gynecol. 1999 Feb;180(2 Pt 2):295-301.

PMID:
9988833
17.

The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.

van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR.

BMJ. 2009 Aug 13;339:b2921. doi: 10.1136/bmj.b2921.

18.

Evidence-based indications for thrombophilia screening.

Lindhoff-Last E, Luxembourg B.

Vasa. 2008 Feb;37(1):19-30. Review.

PMID:
18512539
20.

Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?

Schambeck CM, Schwender S, Haubitz I, Geisen UE, Grossmann RE, Keller F.

Thromb Haemost. 1997 Dec;78(6):1480-3.

PMID:
9423798
Items per page

Supplemental Content

Support Center